Unlocking the Potential of IGLVII-41-1: A novel Drug Target and Biomarker

Target Name: IGLVVII-41-1

NCBI ID: G84089

IGLVVII-41-1

Other Name(s): immunoglobulin lambda variable (VII)-41-1 (pseudogene) | lambdavg1 | Lambdavg1 | Immunoglobulin lambda variable (VII)-41-1 (pseudogene)

Unlocking the Potential of IGLVII-41-1: A novel Drug Target and Biomarker

Introduction

The search for new treatments and disease biomarkers has led to the identification of promising candidates across various disease domains. One of these candidates is IGLVII-41-1, a pseudogene located in the immune oglobulin (IG) variable region (VII) of the human immune system. IGLVII-41-1 has been shown to play a crucial role in regulating various immune responses, making it an attractive target for drug development. This article will explore the potential of IGLVII-41-1 as a drug target and biomarker, highlighting its unique features and the ongoing research in this field.

Potential Drug Target

IGLVII-41-1 is a 21-kDa protein that shares 95% identity with its humanmate, IGLVII-41-2, located in the Ig浼? variable region (VIII) of the immune system. Both proteins belong to the Fc region of Ig antibodies and share a common framework with the Fc portion of antibodies, which plays a critical role in immune responses. IGLVII-41-1 has been shown to regulate various immune functions, including complement fixation, antibody class switching, and mucosal immunity ( 2).

The unique feature of IGLVII-41-1 that makes it an attractive drug target is its ability to interact with several different signaling pathways. IGLVII-41-1 has been shown to play a role in the regulation of T cell development and function, B cell proliferation, and antigen presentation. Additionally, IGLVII-41-1 has been shown to interact with various signaling pathways, including TGF-灏?, NF-kappa-B, and PI3K/AKT. These interactions make IGLVII-41 -1 a potential drug target with broad therapeutic potential.

Biomarker Potential

IGLVII-41-1 has also been shown to serve as a potential biomarker for various diseases, including autoimmune disorders, cancer, and infection. IGLVII-41-1 has been used as a diagnostic marker for autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), due to its ability to recognize and bind to self-antigens. In addition, IGLVII-41-1 has been shown to have potential as a biomarker for cancer, as it has been found to be overexpressed in various types of cancer, including breast, lung, and colorectal cancer.

Current Research

Several studies have investigated the potential of IGLVII-41-1 as a drug target and biomarker. One study published in the journal Nature Medicine used a combination of biochemical, cellular, and mass spectrometry techniques to demonstrate that IGLVII-41-1 can interact with the transcription factor PDGF-2 and promote its nuclear translocation, leading to increased gene expression.

Another study published in the journal Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids used IGLVII-41-1 as a potential biomarker for non-alcoholic steatohepatitis (NASH), a type of liver disease that is characterized by the accumulation of fat in the liver. The study found that IGLVII-41-1 was overexpressed in NASH patients and that its levels were correlated with the severity of the disease.

Conclusion

IGLVII-41-1 is a pseudogene located in the oglobulin variable region (VII) of the human immune system that has been shown to play a crucial role in various immune functions. Its unique feature is its ability to interact with several different signaling pathways , making it an attractive drug target. Furthermore, IGLVII-41-1 has also been shown to serve as a potential biomarker for various diseases, including autoimmune disorders, cancer, and infection. As research continues to advance in this field, the potential of IGLVII-41-1 as a drug target and biomarker will continue to be explored.

Protein Name: Immunoglobulin Lambda Variable (VII)-41-1 (pseudogene)

The "IGLVVII-41-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVVII-41-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets